ClinicalTrials.gg
RecruitingNCT05203250Updated Aug 6, 2025

Longitudinal Registry Including Patients Treated With Heavy Particles

An observational study in Cancer, Oncology and Radiation Exposure, sponsored by CNAO National Center of Oncological Hadrontherapy. Recruiting at 1 site in Italy. Per ClinicalTrials.gov, last updated 2025-08-06.

Sponsored by CNAO National Center of Oncological Hadrontherapy · Observational

How we know

From the registry’s dates

  • Started Jun 2021; still recruiting 5 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
3,000
Sex
All
01

Study summary

The purpose of this registry is to collect retrospective and prospective standardized data of patients treated with particle therapy, either with protons or carbon ions, at the National Center for Oncological Hadrontherapy (CNAO) based in Pavia.

By keeping track of the patients treated, it will allow the investigators to periodically analyze and evaluate data collected of daily clinical activity. This will help gathering more information on the results of particle therapy and will provide the basis for in depth evaluation of patients' outcome with respect to the delivered treatment.

Read the detailed description

Hadrontherapy is a unique radiotherapy (RT) that uses positively charged particles, namely protons and carbons, rather than photons used in conventional RT, to treat cancer.

Particle therapy represents a coming together of physics research applied to oncology and it is currently the most advanced form of radiotherapy for the treatment of tumors that are particularly radio resistant or located nearby sensitive structures.The strength of hadrontherapy lies in the unique physical and radiobiological properties of these particles. Indeed, protons and carbon ions have several biological advantages compared to conventional photon radiotherapy.

In this scenario we aim at constructing a patient registry to retrospectively and prospectively collect real-world data on all cancer patients treated at CNAO, either with protons or carbon ion radiation, independently of their disease (multiple cohorts will be included) for which they were treated.

We aim at collecting data on the natural history of the disease (how the disease presents, develops and progress, its association with other conditions). Those data will allow us to assess prognostic and predictive factors to evaluate treatment effects and toxicities and to provide evidence of the role of radiation oncology in a multidisciplinary approach.

Such registry will be used to generate clinical evidence and high-quality data that could better define the indications for heavy particles therapy and become a resource for the wider scientific community.

02

Conditions studied

  • Cancer
  • Oncology
  • Radiation Exposure
  • Radiotherapy Side Effect
  • Radiation Toxicity
  • Rare Disease

Keywords

  • Hadrontherapy
  • Oncology
  • Cancer
  • Radiotherapy
  • Protons
  • Carbon Ions
  • Heavy ions
  • Rare cancer
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 3,000 is above the median of 200 across 2,644 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

CNAO National Center of Oncological Hadrontherapy is the lead sponsor of 11 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients treated with particle therapy, protons and/or carbon ions, at the National Center for Oncological Hadrontherapy (CNAO), based in Pavia, who have signed the written informed consent document, can be enrolled in the study

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients treated with heavy particles at Fondazione CNAO, Pavia
  • Patients who have the ability to understand and be willing to sign a written document

Exclusion criteria

Exclusion Criteria:

  • Patients or legal guardians who are unable to understand document
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
3,000 participants (estimated)
Target follow-up
50 Years
Patient registry
Yes

Groups and cohorts

  • Brain tumors, skull base tumors, spinal cord tumors

    NEUROPARTICLE

    Radiation: Heavy-ion therapy (hadrontherapy)

  • Ocular melanomas

    Radiation: Heavy-ion therapy (hadrontherapy)

  • Head and Neck tumors

    Radiation: Heavy-ion therapy (hadrontherapy)

  • Tumors of thorax and/or abdomen

    GI-Particle

    Radiation: Heavy-ion therapy (hadrontherapy)

  • Pelvic tumors

    GYN-Particle

    Radiation: Heavy-ion therapy (hadrontherapy)

  • Sarcomas and tumors of limbs

    SarTAP-Particle

    Radiation: Heavy-ion therapy (hadrontherapy)

  • Pediatric tumors

    Radiation: Heavy-ion therapy (hadrontherapy)

  • Mobile spine and sacral tumors

    Radiation: Heavy-ion therapy (hadrontherapy)

Interventions

  • RadiationHeavy-ion therapy (hadrontherapy)

    Only data available from routine clinical practice at the National Center for Oncological Hadrontherapy (CNAO), based Pavia, will be collected. Intervention is not assigned.

06

What researchers measure

Primary outcomes

  1. Real world data collection

    To collect real world data of patients treated with radiotherapy, to support particle radiotherapy and to provide evidence of the role of radiation oncology within the multidisciplinary approach.

    Time frame: 50 years

Secondary outcomes

  1. Disease evolution

    To analyze the disease course and treatment performed by collecting demographic, disease characteristics and delivered treatment

    Time frame: 50 years

  2. Predicitive models

    To collect details about the radiation treatment and radiobiological parameters to develop predictive models (outcome and toxicity)

    Time frame: 50 years

  3. Outcome data

    To collect outcome data (in terms of overall survival, progression free-survival and local control) and to correlate them with the delivered treatment

    Time frame: 50 years

  4. Toxicities

    To define acute, intermediate and late toxicities, according to CTCAE v 5.0 and to correlate it with the delivered treatment

    Time frame: 50 years

  5. QoL

    To collect data on standardized QoL questionnaires and PROMS (e,g EORTC C30, EQDL) at 6, 12. 18, 24, 36 months and to correlate them with the delivered treatment

    Time frame: 50 years

  6. Future research

    To generate hypotheses for further research

    Time frame: 50 years

07

Study locations

1 of 1 sites recruiting
  • National Center for Oncological Hadrontherapy (CNAO)
    Pavia, 27100, Italy
    Recruiting
    • Chiara Campo, PhD · Contactcampo@cnao.it · +39 0382-078 407
    • Cristina Bono · Contactbono@cnao.it · +39 0382078613
    • Ester Orlandi, MD · Principal investigator
08

References and documents

Publications

  • Tinganelli W, Durante M. Carbon Ion Radiobiology. Cancers (Basel). 2020 Oct 17;12(10):3022. doi: 10.3390/cancers12103022. PubMed 33080914 ↗
  • Durante M, Paganetti H. Nuclear physics in particle therapy: a review. Rep Prog Phys. 2016 Sep;79(9):096702. doi: 10.1088/0034-4885/79/9/096702. Epub 2016 Aug 19. PubMed 27540827 ↗
  • Kraft G. The radiobiological and physical basis for radiotherapy with protons and heavier ions. Strahlenther Onkol. 1990 Jan;166(1):10-3. PubMed 2154042 ↗
  • Weber KJ, Flentje M. Lethality of heavy ion-induced DNA double-strand breaks in mammalian cells. Int J Radiat Biol. 1993 Aug;64(2):169-78. doi: 10.1080/09553009314551261. PubMed 8103540 ↗
  • Mizoe JE, Hasegawa A, Jingu K, Takagi R, Bessyo H, Morikawa T, Tonoki M, Tsuji H, Kamada T, Tsujii H, Okamoto Y; Organizing Committee for the Working Group for Head Neck Cancer. Results of carbon ion radiotherapy for head and neck cancer. Radiother Oncol. 2012 Apr;103(1):32-7. doi: 10.1016/j.radonc.2011.12.013. Epub 2012 Feb 8. PubMed 22321201 ↗
  • Weber DC, Langendijk JA, Grau C, Thariat J. Proton therapy and the European Particle Therapy Network: The past, present and future. Cancer Radiother. 2020 Oct;24(6-7):687-690. doi: 10.1016/j.canrad.2020.05.002. Epub 2020 Aug 1. PubMed 32753239 ↗
  • Langendijk JA, Orecchia R, Haustermans K, Zips D, Balosso J, Lacombe D, Lievens Y, Weber DC, Grau C, Troost EGC. Prospective data registration and clinical trials for particle therapy in Europe. Radiother Oncol. 2018 Jul;128(1):9-13. doi: 10.1016/j.radonc.2018.06.001. Epub 2018 Jul 7. PubMed 30056852 ↗
  • Grau C, Durante M, Georg D, Langendijk JA, Weber DC. Particle therapy in Europe. Mol Oncol. 2020 Jul;14(7):1492-1499. doi: 10.1002/1878-0261.12677. Epub 2020 Apr 22. PubMed 32223048 ↗

Related links

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2021 (actual). Primary completion is estimated for Jun 2030, 108 months after the start.

Of 1,099 non-industry observational studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 227. This study's planned 108 months is above that.

Counting every sponsor, half of 1,247 studies reached it within 58 months; a quarter within 24 and three quarters within 210.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2022
First posted
Jan 24, 2022
StartActual
Jun 4, 2021
Primary completionEst.
Jun 4, 2030
CompletionEst.
Jun 4, 2071
Last update
Aug 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05203250
Lead sponsor
CNAO National Center of Oncological Hadrontherapy
Responsible party
Sponsor
First posted
Jan 24, 2022
Start date
Jun 4, 2021
Primary completion
Jun 4, 2030 (estimated)
Completion
Jun 4, 2071 (estimated)
Last update
Aug 6, 2025

Study contacts

Chiara Campo, PhD
Contact
campo@cnao.it
+39 0382078407
Cristina Bono
Contact
bono@cnao.it
+39 0382078613

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion